Considerable interest has focused on the design of modulators of the p53/MDM2 interaction, as inhibition of the human E3 ubiquitin ligase MDM2 leads to reactivation of p53 activity in human glioblastoma cells. This evidence concerns the gene TP53 and glioblastoma.